Deals and Portfolio Review:
Lessons for pharma from a challenging year

Sign me up

What is the webinar about?

2018 was a year of highs and lows. We saw plenty of big dollar deals and blockbuster launches. But as the year progressed, pharma companies became increasingly selective in their dealmaking, sharpening their focus on premium assets.
The new year begins with uncertainty. The BMS-Celgene megamerger was the largest one yet in what looks like a developing trend. Big pharma ushered in the new year with drug price increases in the US - a clear sign that earnings take precedence over politics. Yet, political and economic forces drive a shifting and unpredictable global landscape. The Clarivate Analytics Deals and Portfolio Review is back to help you prepare.
Our experts will dig into the strategies behind last year’s biggest deals and key portfolio decisions.  You’ll hear a breakdown by company, therapeutic area and region. You'll get insight on the region where life sciences dealmaking is rapidly growing. We’ll also take you on a deeper dive into the oncology drug development landscape: Are the drivers in place for its continued dominance in 2019?


Laura Vitez
Life Sciences Senior Deals Analyst
Clarivate Analytics

Laura has over 25 years of experience in the life sciences industry. She has held lead or advisory roles at multiple small biotechs, a mid-sized pharma company, and two consulting firms, bringing in over $2 billion deal dollars. She holds an MS in biochemistry and a BA in mathematics and chemistry.

Jamie Munro
Global Practice Leader, Portfolio & Licensing
Clarivate Analytics

Jamie Munro leads the Portfolio & Licensing practice at Clarivate Analytics including heading up CMR International, the R&D benchmarking service. Dr. Munro has significant life science experience including over 15 years large pharma experience as well as a PhD in Finance.


Webinar details

  • Date Wednesday February 6, 2019
  • Time 10am EST Time I 3pm UK I 4pm CET


We will also provide deeper insights in:

  • - Overview of dealmaking activity throughout 2018, as captured by Cortellis
  • - Insights on the dollar values and volumes by transaction type, therapeutic area and development stage
  • - Examination of long-term trends versus current developments.
  • - A closer look at developments and partnerships in oncology
  • - A summary of key trends and metrics for innovative pharma and what to watch out for in 2019.

Who should Attend:

  • Business Development & Licensing Professionals
  • Partnership & Strategy Leaders
  • Financial Analyst, Venture Capitalist
  • Research Scientist